Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
4 reports, 4 independent
Updated Oct 30
Gone quiet
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Agios Pharmaceuticals gained priority review status for its mitapivat application from the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA classified Agios's response for mitapivat as a major amendment and requested REMS evaluation.1 source
Agios Pharmaceuticals received priority review status for its drug application from the FDA.1 source
Keep exploring
The entities involved
-
Agios Pharmaceuticals
a public American pharmaceutical company
Nothing else this week.
- FDA